Clovis Oncology Inc. shares ticked higher after hours Tuesday following a big jump in the regular session as the Food and Drug Administration accepted a marketing application for the company's ovarian cancer treatment and granted it a priority review process. Clovis shares advanced 1% to $23.25 after hours, following a 23% rally in the regular session. The FDA is expected to make a decision on the application by Feb. 23, 2017. Studies of Clovis's treatment rucaparib showed 54% of patients with recurring ovarian cancer responded to the treatment.
Copyright © 2016 MarketWatch, Inc.